(Q39618014)

13 September 2017

1 reference

title

A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders (English)

2 references

13 September 2017

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

19 June 2022

author name string

R. J. Wyatt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A320322

19 June 2022

J. S. Torgow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A320322

19 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=320322

19 June 2022

publication date

1 January 1977

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:0022395677900115?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

https://api.elsevier.com/content/article/PII:0022395677900115?httpAccept=text/plain

19 June 2022

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Journal of Psychiatric Research

19 June 2022

published in

1 reference

13 September 2017

volume

13

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

91-98

1 reference

The comparative effectiveness of eight phenothiazines

13 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients

19 June 2022

4

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Predicting response to phenothiazines: the right drug for the right patient

19 June 2022

5

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Drug Treatment in Newly Admitted Schizophrenic Patients

19 June 2022

6

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE AND CHLORPROMAZINE.

19 June 2022

8

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Chlorprothixene ("Truxal") compared to chlorpromazine

19 June 2022

9

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Clinical studies with clopenthixol (sordinol) on chronic psychiatric patients

19 June 2022

10

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

The place of thiothixene among the thioxanthenes

19 June 2022

11

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Prediction of response to phenothiazines in schizophrenia. A crossvalidation study

19 June 2022

12

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients

19 June 2022

14

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A CLINICAL COMPARISON OF TRIFLUPERIDOL, HALOPERIDOL, AND CHLORPROMAZINE

19 June 2022

15

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

COMPARISON OF HALOPERIDOL, TRIFLUPERIDOL, AND CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC PATIENTS

19 June 2022

17

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Haloperidol and thioridazine in treatment of chronic schizophrenics

19 June 2022

18

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A Comparative Trial of Haloperidol and Thioridazine: Management of Chronic Schizophrenia

19 June 2022

21

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics

19 June 2022

22

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Pimozide in the treatment of chronic schizophrenic patients

19 June 2022

23

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.

19 June 2022

24

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A Study of Thioridazine and Its Side-Chain Derivative, Mesoridazine, in Chronic Male Hospitalized Psychiatric Patients

19 June 2022

28

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A COMPARATIVE STUDY OF OXYPERTINE AND TRIFLUOPERAZINE IN CHRONIC SCHIZOPHRENIA--A NEW APPLICATION OF THE WING RATING SCALE

19 June 2022

29

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia

19 June 2022

31

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Oxypertine and thiothixene in newly admitted schizophrenic patients; A further search for specific indications of antipsychotic drugs

19 June 2022

32

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A Comparison of the Effects of Oxypertine and Trifluoperazine in Withdrawn Schizophrenics

19 June 2022

33

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Oxypertine. A review of clinical experience

19 June 2022

34

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients

19 June 2022

36

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Loxapine: a controlled evaluation in chronic schizophrenic patients

19 June 2022

37

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital

19 June 2022

38

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness.

19 June 2022

40

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A study of phenothiazines with male and female chronically ill schizophrenic patients

19 June 2022

41

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Thiothixene, thioridazine, and placebo in male chronic schizophrenic patients

19 June 2022

44

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Double Blind Comparison of Thiothixene and Trifluoperazine in Acute Schizophrenia

19 June 2022

45

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

IMIPRAMINE AND THIORIDAZINE IN DEPRESSED AND SCHIZOPHRENIC PATIENTS. ARE THERE SPECIFIC ANTIDEPRESSANT DRUGS?

19 June 2022

48

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

The direct comparison of antidepressants: imipramine and chlorprothixene.

19 June 2022

50

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Acetophenazine and Diazepam in Anxious Depressions

19 June 2022

51

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol

19 June 2022

52

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A comparative double-blind trial of pimozide in stress-induced psychic and functional disorders

19 June 2022

53

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Drug Treatment of Anxiety and Depression in Detoxified Alcoholic Patients

19 June 2022

54

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

The treatment of mixed anxiety and depression with loxapine: a controlled comparative study.

19 June 2022

55

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Drug therapy of depression. Amitriptyline, perphenazine, and their combination in different syndromes

19 June 2022

57

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Role of antidepressants and neuroleptics in the treatment of depression

19 June 2022

58

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

COMPARISON OF DIAZEPAM, CHLORPROMAZINE AND A PLACEBO IN PSYCHIATRIC PRACTICE.

19 June 2022

59

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A Comparative Trial of Imipramine and Chlorpromazine in Depressed Patients

19 June 2022

60

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients.

19 June 2022

61

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Dose equivalence of the antipsychotic drugs

19 June 2022

63

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

A rating scale for depression

19 June 2022

65

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Reflections on the Specificity of Action of Anti-Depressants

19 June 2022

66

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

An anatomy of schizophrenia?

19 June 2022

67

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

Mental illness in the biological and adoptive families of adpoted schizophrenics

19 June 2022

A double-blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics

68

0 references

26

1 reference

https://api.crossref.org/works/10.1016/0022-3956(77)90011-5

15 March 2023

Identifiers

1 reference

13 September 2017

1 reference